文献速递新生儿儿童感染

母婴阿片类药物筛查识别新生儿阿片戒断综合征风险

Maternal and Infant Opioid Screening for Neonates at Risk.
PubMed 文献 · Pediatrics · 2025-01-01

该回顾性研究评估了母亲病史与体检、母亲尿药筛查和新生儿尿药筛查三种方式识别新生儿阿片戒断综合征(NOWS)风险的能力。在460名新生儿中,98.3%由母亲筛查识别,新生儿尿药筛查未额外识别需要监测的新生儿,母亲阿片使用史对识别需治疗新生儿的敏感性为96.1%。

要点

  • 母亲筛查(病史或尿药筛查)识别了98.3%的NOWS风险新生儿。
  • 新生儿尿药筛查未额外识别需要NOWS监测的新生儿。
  • 母亲阿片使用史识别需治疗NOWS新生儿的敏感性为96.1%。

核心结论

  • 包括病史和尿药筛查在内的母亲筛查方式识别了几乎所有需要NOWS监测的新生儿。
  • 新生儿尿药筛查未识别额外的高风险新生儿。

研究设计与样本

  • 回顾性病历审查,纳入2017年1月1日至2022年1月1月在马里兰大学医学中心有新生儿Finnegan评分记录的新生儿,共460名。

主要发现

  • 460名新生儿中,452名(98.3%)通过母亲筛查(母亲阿片使用史或母亲尿药筛查阳性)识别。
  • 没有新生儿仅基于新生儿尿药筛查结果接受NOWS监测。
  • 母亲阿片使用史对识别接受NOWS治疗的新生儿敏感性为96.1%。

关键数值与推荐

  • 机构药物干预标准为连续2次或以上Finnegan评分≥9分。
  • 治疗接受定义为有因戒断而使用吗啡的记录。

临床怎么用

  • 母亲病史和尿药筛查可识别绝大多数需要NOWS监测的新生儿。
  • 新生儿尿药筛查未显示额外识别高风险新生儿的价值。

局限性

  • 原文未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Identifying neonates at risk for neonatal opioid withdrawal syndrome (NOWS) is important to ensure adequate monitoring and treatment. We sought to evaluate 3 screening modalities-maternal history and physical (H&P), maternal urine drug screening (MUDS), and neonatal urine drug screening (NUDS)-in the identification of neonates at risk for NOWS. METHODS: Retrospective chart review was conducted for neonates with documented neonatal Finnegan scores at the University of Maryland Medical Center in Baltimore, Maryland, from January 1, 2017, through January 1, 2022. Maternal H&P was reviewed in addition to MUDS and NUDS. The institution's criterion for pharmacologic intervention is 2 or more consecutive Finnegan scores of 9 or greater. Treatment receipt was defined as documentation of morphine administration for treatment of withdrawal. RESULTS: Of the 460 neonates included, most (452 (98.3%) were identified by maternal screening, which included a documented maternal history of opioid use or a positive MUDS result. No neonates received monitoring for NOWS based solely on NUDS. Maternal history of opioid use also had the highest sensitivity for identifying neonates who received treatment for NOWS (96.1%). CONCLUSION: Maternal screening modalities including history and urine toxicology identify almost all neonates who require monitoring for NOWS. NUDS did not identify additional at-risk neonates. Prospective studies are warranted to assess a balanced approach to NUDS that prioritizes newborn safety while reducing maternal stigmatization and minimizing separation.

来源:Pediatrics,查看原文。版权归原作者所有。

引用

  1. Witcher KG, Huddleson A, Soltanian A, et al. Maternal and Infant Opioid Screening for Neonates at Risk. Pediatrics. 2025. PMID: 40789584. doi:10.1542/peds.2024-068612

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。